Kodiak Sciences opened lower at $99.41, compared with its previous close of $100.40. In the last trading session, the stock traded between $96.58 and $100.69. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Kodiak Sciences is now worth
$ 84.18
resulting in a loss of
$ 15.82 (15.82%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 7 Analysts
Buy
85.71%
Hold
14.29%
Sell
0%
Markets Today
Today's Change
$-1.84 (-1.83%)
Day High
$100.69
Day Low
$96.58
Day Open
$99.41
Prev Close
$100.40
Volume
2,12,625
1W Return
14.91%
1M Return
8.15%
3M Return
145.79%
6M Return
125.70%
1Y Return
420.68%
Fundamentals
Market Cap ($ Mn)
6,195
PE Ratio
-
PB Ratio
38.71
PEG Ratio
-
ROE
-225.24%
ROCE
-91.28%
EPS (TTM)
$-1.04
Investment Returns
1 Week
14.91%
1 Month
8.15%
3 Months
145.79%
6 Months
125.70%
9 Months
287.59%
Financials
Quarterly
All values in $ Mn
0.0
Dec 24
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
Updates
21Oct
Kodiak Sciences files shelf prospectus for offering
Kodiak Sciences Inc. filed a shelf prospectus with the SEC. The size of the offering is not disclosed in the filing. Registration allows for future sale of securities.
9 days ago
28Sep
Kodiak Sciences shares jump 137% on positive Phase 3 wAMD data
Kodiak Sciences shares surged 137.09% to $76.70 following positive Phase 3 DAYBREAK study results. UBS analyst Michael Yee maintained a Buy rating and raised the price target from $80 to $120. Both Zenkuda and KSI-501 met primary endpoints for non-inferiority versus Eylea in treating wAMD. Zenkuda achieved a p-value of 0.0007, while KSI-501 achieved a p-value of 0.0036 for vision endpoints.
1mo ago
11Aug
Kodiak Sciences enrols first patients in Phase 3 ALTO trial for KSI-501
Kodiak Sciences Inc. has begun patient enrollment in the Phase 3 ALTO trial for KSI-501, a bispecific therapy for diabetic macular edema. The study compares KSI-501 against aflibercept, testing intensive and individualized dosing regimens with intervals up to six months. This follows the DAYBREAK Phase 3 trial for wet AMD, highlighting the platform's potential across retinal diseases.
